FDA sets PDUFA action date for January 5, 2022
If approved, BXCL501 would represent the first major advancement in the acute treatment of agitation associated with schizophrenia and bipolar disorders in almost a decade
https://finance.yahoo.com/news/bioxcel-therapeutics-announces-fda-acceptance-110000657.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.